SCHEMBL23723451

SCHEMBL23723451

CN1CCN(CCNc2nc(NCCc3ccccn3)nc3ccccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.50
GBA1 P04062 1/20 0.50
SUMO3 P55854 1/20 0.49
SUMO2 P61956 1/20 0.49
SUMO1 P63165 1/20 0.49
APP P05067 3/20 0.49
BCHE P06276 3/20 0.49
ACHE P22303 3/20 0.49
TLR9 Q9NR96 2/20 0.48
SLC2A1 P11166 3/20 0.46
KAT2B Q92831 1/20 0.45
PDE5A O76074 1/20 0.44
FLT3 P36888 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30621754 1.00 HRH4 (0.50) HRH4GBA1SUMO3SUMO2SUMO1
SCHEMBL23723437 0.86 APP (0.67) HRH4APPBCHEACHETLR9
SCHEMBL30125347 0.86 APP (0.67) HRH4APPBCHEACHETLR9
SCHEMBL30621745 0.84 HRH4 (0.59) HRH4APPBCHEACHETLR9
SCHEMBL23723446 0.84 HRH4 (0.59) HRH4APPBCHEACHETLR9
SCHEMBL23723465 0.82 HRH4 (0.59) HRH4GBA1APPBCHEACHE
SCHEMBL23723417 0.82 ACHE (0.61) HRH4APPBCHEACHETLR9
SCHEMBL23747956 0.82 HRH4 (0.51) HRH4APPBCHEACHETLR9
SCHEMBL23723470 0.82 HSD17B10 (0.52) HRH4APPBCHEACHETLR9
SCHEMBL30125147 0.82 HRH4 (0.59) HRH4GBA1APPBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2023-10-26 US disclosed
EP-4100395-A1 QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER Trobio Therapeutics Pty Ltd (AU) 2022-12-14 EP disclosed
WO-2021155426-A1 QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2021-08-12 WO disclosed
WO-2021155426-A1 QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer NQO2, TP53, ABL1 HRH4 1715/4885GBA1 1282/4885SUMO3 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.